COCP: Cocrystal Pharma Inc. Stocks News on April 24, 2025

Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

COCP

GlobeNewswire

5 hours ago

Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference

COCP

GlobeNewswire

8 days ago

Cocrystal Pharma to Present at Life Science Innovation Northwest 2025 Conference

COCP

Zacks Small Cap Research

14 days ago

OTC Markets Hosts Virtual Investor Presentation with Dr. Sam Lee, Co-CEO & President, and Jim Martin, Co-CEO & CFO, of Cocrystal Pharma, with David Bautz, PhD, Senior Analyst at Zacks SCR

COCP

Zacks Small Cap Research

23 days ago

COCP: Norovirus Challenge Study Planned for 2025…

Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

COCP

GlobeNewswire

24 days ago

Cocrystal Pharma Reports 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

COCP

GlobeNewswire

a month ago

Life Science Virtual Investor Forum: Presentations Now Available for Online Viewing

Life Sciences Investor Forum Agenda Announced for March 13th

COCP

GlobeNewswire

a month ago

Life Sciences Investor Forum Agenda Announced for March 13th

Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025

COCP

GlobeNewswire

2 months ago

Cocrystal Pharma to Participate in a Fireside Chat at the Zacks SCR Life Sciences Virtual Investor Forum on March 13, 2025

Cocrystal Pharma And 2 Other Promising US Penny Stocks To Watch

COCP

Simply Wall St.

2 months ago

Cocrystal Pharma And 2 Other Promising US Penny Stocks To Watch

COCP

Zacks Small Cap Research

4 months ago

COCP: Phase 2a Trial of CC-42344 Extended…

Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections

COCP

GlobeNewswire

4 months ago

Cocrystal Pharma Reports Phase 1 Results with Oral, Broad-Acting Antiviral Drug CDI-988 for Prophylaxis and Treatment of Norovirus, Coronaviruses and Other Viral Infections

Cocrystal to extend enrolment in Phase IIa influenza inhibitor trial

COCP

Clinical Trials Arena

4 months ago

Cocrystal to extend enrolment in Phase IIa influenza inhibitor trial

Cocrystal Pharma Shares Drop 35% Following Phase 2a Study Extension Announcement

COCP

GuruFocus.com

4 months ago

Cocrystal Pharma Shares Drop 35% Following Phase 2a Study Extension Announcement

COCP

MT Newswires

4 months ago

Top Midday Decliners

COCP

MT Newswires

4 months ago

Cocrystal Pharma Extends Phase 2A Influenza Challenge Study; Shares Fall

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

COCP

GlobeNewswire

4 months ago

Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344

US Penny Stocks To Watch In December 2024

COCP

Simply Wall St.

4 months ago

US Penny Stocks To Watch In December 2024

COCP

Zacks Small Cap Research

5 months ago

COCP: Multiple Upcoming Catalysts…

November 2024 US Exchange Standouts: Promising Penny Stocks

COCP

Simply Wall St.

5 months ago

November 2024 US Exchange Standouts: Promising Penny Stocks

Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

COCP

GlobeNewswire

5 months ago

Cocrystal Pharma Reports Third Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins

COCP

GlobeNewswire

6 months ago

Cocrystal Pharma’s Co-CEOs Highlight Pioneering Approach to Antiviral Drug Candidates Targeting Influenza and Coronaviruses as Fall Flu and COVID Season Begins

COCP

Simply Wall St.

6 months ago

Here's Why We're Watching Cocrystal Pharma's (NASDAQ:COCP) Cash Burn Situation

Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts

COCP

GlobeNewswire

7 months ago

Cocrystal Pharma Advances Oral Pan-Viral Protease Inhibitor CDI-988 into Phase 1 Multiple-Ascending Dose Cohorts

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

COCP

GlobeNewswire

8 months ago

Cocrystal Pharma to Highlight Near-term Clinical Milestones During Presentations at Two Upcoming Investment Conferences

COCP

Zacks Small Cap Research

8 months ago

COCP: Topline Results from Phase 2a Study of CC-42344 in 2H24…

COCP

ACCESSWIRE

8 months ago

CoCrystal Pharma to Present at August 20th Virtual Investor Summit Microcap Event

Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

COCP

GlobeNewswire

8 months ago

Cocrystal Pharma Reports Second Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

COCP

Zacks Small Cap Research

9 months ago

COCP: Phase 1 Single-Ascending Dose Cohort of CDI-988 Shows it is Safe and Well Tolerated…

Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

COCP

GlobeNewswire

9 months ago

Cocrystal Pharma Reports Favorable Results from Single-Ascending Dose Cohorts of Phase 1 Study with CDI-988, its Oral Pan-Viral Norovirus/Coronavirus Protease Inhibitor

COCP

Zacks Small Cap Research

10 months ago

COCP: CC-42344 Shows In Vitro Activity Against Avian Influenza A (H5N1)…

New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows

COCP

GlobeNewswire

10 months ago

New Broad-Spectrum Antiviral Currently in a Phase 2a Clinical Trial in Influenza A may be Effective Against the H5N1 Avian Influenza Strain Identified in Humans Exposed to Infected Dairy Cows

COCP

Motley Fool

a year ago

Better AI Stock: Palantir vs. Snowflake

Is Now the Time to Buy 3 of the S&P 500's Highest-Yielding Dividend Stocks?

COCP

Motley Fool

a year ago

Is Now the Time to Buy 3 of the S&P 500's Highest-Yielding Dividend Stocks?

COCP

Motley Fool

a year ago

BigBear.ai Stock: Buy, Sell, or Hold?

Indonesia's first Olympic gymnast encourages others to 'dream higher'

COCP

AFP

a year ago

Indonesia's first Olympic gymnast encourages others to 'dream higher'

Where Will CrowdStrike Stock Be in 1 Year?

COCP

Motley Fool

a year ago

Where Will CrowdStrike Stock Be in 1 Year?

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp

COCP

GuruFocus.com

a year ago

Warren Buffett's Strategic Acquisition in Occidental Petroleum Corp

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...

COCP

GuruFocus.com

a year ago

Insider Sale: EVP, CEO of Patient Direct, Perry Bernocchi, Sells Shares of Owens & Minor ...

A Look At The Intrinsic Value Of Deufol SE (HMSE:DE1)

COCP

Simply Wall St.

a year ago

A Look At The Intrinsic Value Of Deufol SE (HMSE:DE1)

COCP

Zacks

a year ago

Cocrystal Pharma, Inc. (COCP) Now Trades Above Golden Cross: Time to Buy?

COCP

Zacks Small Cap Research

a year ago

COCP: Enrollment Complete in Phase 2a Human Challenge Trial of CC-42344…

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

COCP

GlobeNewswire

a year ago

Cocrystal Pharma Reports First Quarter 2024 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

COCP

GlobeNewswire

a year ago

Enrollment Completed in Phase 2a Study with Cocrystal Pharma’s Oral Antiviral Candidate CC-42344 for Pandemic and Seasonal Influenza

COCP

Zacks Small Cap Research

a year ago

COCP: Topline Data for Influenza A and Dual Coronavirus/Norovirus Programs Expected in 2024; Model Revision Leads to Valuation of $6 Per Share…

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

COCP

GlobeNewswire

a year ago

Cocrystal Pharma Reports 2023 Financial Results and Provides Updates on its Antiviral Drug-Development Programs

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

COCP

GlobeNewswire

a year ago

Cocrystal Pharma Receives Pre-IND Responses from the FDA on Oral CC-42344 for Treating Influenza A

COCP

ACCESSWIRE

a year ago

Cocrystal Pharma Discusses Antiviral Therapeutics' Clinical Development and 2024 Value Catalysts in New CEO Video Interview on Planet MicroCap

COCP

Zacks Small Cap Research

a year ago

COCP: Cocrystal Pharma provides updates on its clinical programs.

SU Group Holdings Reports 20% Revenue Growth For Fiscal Year 2023

COCP

PR Newswire

a year ago

SU Group Holdings Reports 20% Revenue Growth For Fiscal Year 2023

5E Advanced Materials, Inc. Provides Update Confirming Boric Acid and Lithium at 5E Boron Americas Complex

COCP

GlobeNewswire

a year ago

5E Advanced Materials, Inc. Provides Update Confirming Boric Acid and Lithium at 5E Boron Americas Complex

Texas Municipality Expands Use of Knightscope Emergency Communications

COCP

Business Wire

a year ago

Texas Municipality Expands Use of Knightscope Emergency Communications

Jayud Announces Entry into Agreements to Acquire Two International Logistics Companies, Embarking on an Acquisition Strategy to Expand Service Offerings and Geographic Footprint

COCP

PR Newswire

a year ago

Jayud Announces Entry into Agreements to Acquire Two International Logistics Companies, Embarking on an Acquisition Strategy to Expand Service Offerings and Geographic Footprint

POET Technologies Provides Update on Non-Brokered Private Placement

COCP

GlobeNewswire

a year ago

POET Technologies Provides Update on Non-Brokered Private Placement

Loss-Making Beam Global (NASDAQ:BEEM) Expected To Breakeven In The Medium-Term

COCP

Simply Wall St.

a year ago

Loss-Making Beam Global (NASDAQ:BEEM) Expected To Breakeven In The Medium-Term

U.S. Gold Corp. to Participate at the 2024 Future Minerals Forum in Riyadh, Saudi Arabia

COCP

PR Newswire

a year ago

U.S. Gold Corp. to Participate at the 2024 Future Minerals Forum in Riyadh, Saudi Arabia

BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer

COCP

GlobeNewswire

a year ago

BriaCell Images Confirm Robust Anti-Tumor Activity in Patient with “Eye-Bulging” Metastatic Breast Cancer

Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event

COCP

GlobeNewswire

a year ago

Kineta to Participate in the 13th Annual LifeSci Partners Corporate Access Event

Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates

COCP

GlobeNewswire

a year ago

Cocrystal Pharma Provides an Update on the Clinical Development of its Novel, Broad-Spectrum Antiviral Investigational Candidates

Chamonix, Colorado’s Newest and Most Luxurious Casino Hotel, Opens at Noon on Wednesday, December 27, 2023

COCP

GlobeNewswire

a year ago

Chamonix, Colorado’s Newest and Most Luxurious Casino Hotel, Opens at Noon on Wednesday, December 27, 2023

TMC Subsidiary NORI Shares Preliminary Findings on Environmental Impacts of Pilot Nodule Collection System Test

COCP

GlobeNewswire

a year ago

TMC Subsidiary NORI Shares Preliminary Findings on Environmental Impacts of Pilot Nodule Collection System Test

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

COCP

GlobeNewswire

a year ago

Cocrystal Pharma Announces First-Patient-In for Phase 2a Human Challenge Study Evaluating Oral CC-42344 in Pandemic and Seasonal Influenza A

Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to January 3, 2024

COCP

GlobeNewswire

a year ago

Vision Sensing Acquisition Corp. Announces Payment of Fee to Extend Period to Consummate Initial Business Combination to January 3, 2024

Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

COCP

GlobeNewswire

a year ago

Gain Therapeutics Announces Preclinical Data Showing Restoration of Enzymatic Function with Novel Allosteric Regulators in GM1 Gangliosidosis Model

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

COCP

GlobeNewswire

a year ago

Cocrystal Pharma Highlights its Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

COCP

GlobeNewswire

a year ago

Cocrystal Pharma to Present at the NobleCon 19 Conference on December 4, 2023

CPI Aerostructures Receives $4.4M Orders from Embraer for Engine Inlet Assemblies

COCP

GlobeNewswire

a year ago

CPI Aerostructures Receives $4.4M Orders from Embraer for Engine Inlet Assemblies

Quantum Computing Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

COCP

PR Newswire

a year ago

Quantum Computing Inc. to Present at The Benchmark Company's Upcoming Discovery One-on-One Investor Conference

COCP

Zacks Small Cap Research

a year ago

COCP: Cocrystal Pharma reports 3rd quarter financial results and provides updates on clinical trials.

Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs

COCP

GlobeNewswire

a year ago

Cocrystal Pharma Reports Third Quarter 2023 Financial Results and Provides Updates on its Antiviral Drug Development Programs

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

COCP

GlobeNewswire

a year ago

Cocrystal Pharma to Discuss Progress with Novel Inhaled and Oral Influenza A Antiviral CC-42344 at the World Vaccine Congress West Coast

CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

COCP

PR Newswire

a year ago

CalciMedica Reports Third Quarter 2023 Financial Results and Provides Clinical & Corporate Updates

Paltalk, Inc. Reports an Increase in Revenue of 5.5% in Third Quarter 2023

COCP

GlobeNewswire

a year ago

Paltalk, Inc. Reports an Increase in Revenue of 5.5% in Third Quarter 2023

Billionaire Marc Lasry’s Top 10 Stock Picks

COCP

Insider Monkey

a year ago

Latest Cocrystal Pharma Inc. (COCP) News on April 24, 2025

Share on Social Networks: